← Back to headlines
Wedbush Maintains Bullish Stance on Nuvation Bio (NUVB) Following Safusidenib Rights Expansion
Wedbush analysts are bullish on Nuvation Bio after the company expanded its rights for the drug Safusidenib, signaling positive developments for the biotech firm.
12 Apr, 21:54 — 12 Apr, 21:54
Sources
Showing 1 of 1 sources
